A Phase 3 interventional study of ISL and FTC/TDF in HIV Preexposure Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Terminated at 25 sites in 7 countries. Open to male participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men and who are at high risk of HIV-1 infection with 48 or 96 weeks of treatment and a minimum follow-up of 42 days.
Based on laboratory findings of decreased lymphocyte and CD4+ T-cell counts across the islatravir program, dosing of blinded study intervention was halted on 13-Dec-2021. Blinded assessments conducted prior to then are designated as Study Part 1. During Study Part 2, participants from Part 1 were switched to PrEP therapy with emtricitabine/tenofovir disoproxil (FTC/TDF) or emtricitabine/tenofovir alafenamide (FTC/TAF) while continuing in the study, but participants, investigators, and Sponsor personnel remained blinded to the Part 1 treatment. In Part 3, participants, investigators, and all Sponsor personnel are unblinded to participant's original randomized intervention group, and participants may continue to receive unblinded FTC/TDF or FTC/TAF.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 60 mg tablet of ISL QM, orally plus Placebo to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) tablet once daily (QD) or Placebo to Emtricitabine/Tenofovir Alafenamide (FTC/TAF) tablet QD, orally for up to 24 months of treatment duration.
Drug: ISL · Drug: Placebo to FTC/TDF · Drug: Placebo to FTC/TAF
Participants receive 200/245 mg or 200/300 mg of FTC/TDF combination tablet, QD, orally or 200/25 mg of FTC/TAF combination tablet, QD, orally at investigator's discretion plus Placebo to ISL tablet QM, orally for up to 24 months of treatment duration.
Drug: FTC/TDF · Drug: FTC/TAF · Drug: Placebo to ISL
ISL 60 mg tablet, QM, orally for up to 24 months
Also known as: MK-8591
Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
Also known as: Truvada, Emtricitabine/Tenofovir Disoproxil Fumarate
Drug page: Emtricitabine tenofovir alafenamide
Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
Also known as: Descovy, Emtricitabine/Tenofovir Alafenamide
Placebo ISL 0 mg tablets QM, orally for up to 24 months.
Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.
Time frame: Up to approximately 10.5 months
Number of Participants Who Discontinued From Blinded Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.
Time frame: Up to approximately 9 months
Number of Participants With Confirmed HIV-1 Infection
The number of participants with confirmed HIV-1 infections during the blinded treatment period is presented.
Time frame: Up to approximately 10.5 months
| Milestone | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF |
|---|---|---|
| Started | 328 | 166 |
| Completed | 0 | 0 |
| Not completed | 328 | 166 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 7 | 2 |
| Withdrew: Multiple reasons (primarily discontinuation of blinded treatment) | 308 | 160 |
| Withdrew: Withdrawal by subject | 12 | 4 |
| Milestone | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF |
|---|---|---|
| Started | 306 | 154 |
| Completed | 0 | 0 |
| Not completed | 306 | 154 |
| Withdrew: Lost to follow-up | 34 | 9 |
| Withdrew: Not reported | 6 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Study terminated by sponsor | 227 | 119 |
| Withdrew: Withdrawal by subject | 39 | 23 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.
| Participants | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment | 211 | 128 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.
| Participants | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF |
|---|---|---|
| Number of Participants Who Discontinued From Blinded Study Treatment Due to an AE | 1 | 0 |
The number of participants with confirmed HIV-1 infections during the blinded treatment period is presented.
| Participants | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF |
|---|---|---|
| Number of Participants With Confirmed HIV-1 Infection | 0 | 0 |
Collected over Entire Study: Blinded Treatment (Part 1) + Open-Label Standard-of-Care Treatment (Parts 2 & 3) [Up to approximately 26 months]. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: ISL | 0/328 (0%) | 6/328 (1.8%) | 120/328 (36.6%) |
| Parts 2 & 3: Open-label PrEP (ISL in Part 1) | 0/306 (0%) | 18/306 (5.9%) | 230/306 (75.2%) |
| Part 1: FTC/TDF or FTC/TAF | 0/166 (0%) | 1/166 (0.6%) | 88/166 (53%) |
| Parts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1) | 0/154 (0%) | 5/154 (3.2%) | 104/154 (67.5%) |
| Event | Part 1: ISL | Parts 2 & 3: Open-label PrEP (ISL in Part 1) | Part 1: FTC/TDF or FTC/TAF | Parts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1) |
|---|---|---|---|---|
| COVID-19Infections and infestations | 1/328 | 8/306 | 1/166 | 1/154 |
| AppendicitisInfections and infestations | 1/328 | 0/306 | 0/166 | 2/154 |
| Upper respiratory tract infectionInfections and infestations | 0/328 | 0/306 | 0/166 | 1/154 |
| Suicidal ideationPsychiatric disorders | 0/328 | 0/306 | 0/166 | 1/154 |
| CellulitisInfections and infestations | 0/328 | 1/306 | 0/166 | 0/154 |
| Dengue feverInfections and infestations | 0/328 | 1/306 | 0/166 | 0/154 |
| Peritonsillar abscessInfections and infestations | 0/328 | 1/306 | 0/166 | 0/154 |
| Pyelonephritis acuteInfections and infestations | 0/328 | 1/306 | 0/166 | 0/154 |
| Viral infectionInfections and infestations | 0/328 | 1/306 | 0/166 | 0/154 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/328 | 1/306 | 0/166 | 0/154 |
| Event | Part 1: ISL | Parts 2 & 3: Open-label PrEP (ISL in Part 1) | Part 1: FTC/TDF or FTC/TAF | Parts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1) |
|---|---|---|---|---|
| COVID-19Infections and infestations | 35/328 | 69/306 | 21/166 | 37/154 |
| Proctitis chlamydialInfections and infestations | 20/328 | 65/306 | 14/166 | 27/154 |
| Proctitis gonococcalInfections and infestations | 13/328 | 51/306 | 15/166 | 30/154 |
| Oropharyngeal gonococcal infectionInfections and infestations | 16/328 | 41/306 | 11/166 | 24/154 |
| Upper respiratory tract infectionInfections and infestations | 10/328 | 31/306 | 8/166 | 17/154 |
| SyphilisInfections and infestations | 10/328 | 19/306 | 7/166 | 15/154 |
| InfluenzaInfections and infestations | 4/328 | 14/306 | 6/166 | 14/154 |
| NasopharyngitisInfections and infestations | 14/328 | 27/306 | 7/166 | 11/154 |
| CD4 lymphocytes decreasedInvestigations | 1/328 | 24/306 | 3/166 | 6/154 |
| DiarrhoeaGastrointestinal disorders | 19/328 | 14/306 | 9/166 | 11/154 |
| Age, Continuous(years) | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF | Total |
|---|---|---|---|
| Mean | 29.6 ± 9.6 | 29.5 ± 9.2 | 29.6 ± 9.5 |
| Sex: Female, Male(Participants) | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 328 | 166 | 494 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF | Total |
|---|---|---|---|
| Hispanic or Latino | 111 | 51 | 162 |
| Not Hispanic or Latino | 214 | 111 | 325 |
| Unknown or Not Reported | 3 | 4 | 7 |
| Race (NIH/OMB)(Participants) | Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF | Parts 1 to 3: FTC/TDF or FTC/TAF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 70 | 31 | 101 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 83 | 41 | 124 |
| White | 135 | 71 | 206 |
| More than one race | 35 | 20 | 55 |
| Unknown or Not Reported | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2021 to primary completion in Aug 2023, 28 months.
Results were first posted in Dec 2024, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Islatravir